Tirzepatide
TR5
Lyophilized peptide for use under a licensed healthcare provider. Choose single ampule/vial or box of 10. Sourced via Ares Technology Limited (Hong Kong) / Healthtide Biotech manufacturing list dated 7 October 2026. Specification: 5 mg × 10 vials.
- • Prescription / clinician-supervised pathway
- • Same LIRAVEXIN cart and checkout as pen packages
- • Not medical advice — individual suitability is determined by your clinician
Clinical reference (clinician-supervised)
Tirzepatide combines glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonism. Labeled uses include improving glycemic control in type 2 diabetes and reducing excess body weight with long-term maintenance in adults with obesity or overweight with comorbidity; obstructive sleep apnea labeling exists on certain weight-management presentations. Clinic programs use supervised weekly titration to balance efficacy and gastrointestinal tolerability. Catalog strengths (including very high mg vials) are bulk presentations for licensed pathways—they are not equivalent to a finished weekly pen dose. The clinician maps vial content to the prescribed weekly milligram dose after pharmacy compounding where applicable.
Labeled SC titration: start 2.5 mg once weekly for 4 weeks (initiation only), then 5 mg; increase by 2.5 mg increments after ≥4 weeks on the current dose. Adult maximum generally 15 mg once weekly. Maintenance commonly 5, 10, or 15 mg (indication-dependent).
Once weekly subcutaneous injection.
Subcutaneous; rotate sites.
Typical clinical / literature ranges under clinician supervision — not a prescription and not a DIY dosing guide. Individual dosing is determined solely by the treating clinician.
Liravexin USD for this pack (wholesale comparison · source × 3). Item is added to your shared cart for checkout coordination with your clinician pathway.
Or continue to checkout →